Investors Are Likely To Focus On 'What's New' During Johnson & Johnson's Second Quarter Earnings

While we believe that J&J's results will be impacted negatively by exchange rate movements, the company will try to focus on the sales ramp up of its new drugs during its earnings conference call on July 14th to send a positive signal to analysts and investors. With Remicade going off patent and Olysio's sales plummeting, J&J needs new catalysts to drive its growth. Considering the stunted progress and increased competition in medical devices market, these new catalysts have to be in the form of...